The case of an Andalusian child with epidermolysis bullosa -the disease known as “butterfly skin”- has accelerated the institutional response in the community. Recently, the Government of Andalusia has announced that it will finance an innovative treatment while the central Government continues to evaluate its incorporation into the national health system. The decision places the region on the path of countries like the United States, France or Italy, where research and access to advanced therapies for this pathology have already begun to consolidate.
A rare and devastating disease
Epidermolysis bullosa, popularly known as “butterfly skin”, is a rare genetic disease characterized by extreme skin fragility. The slightest touch can cause blisters, chronic wounds, and infections. In its most severe forms, the disease also affects mucous membranes and internal organs and can reduce life expectancy.
In Spain approximately 500 people live with this pathology, a reduced figure that, paradoxically, explains part of the difficulties to develop and finance innovative treatments. Research into rare diseases usually faces very high costs and very small markets.
In data
How a patient's life can change
For those suffering from epidermolysis bullosa -known as “butterfly skin”- daily life is marked by pain, constant dressings and the extreme fragility of the skin. A simple touch can cause blisters or open wounds that take weeks or months to heal. Many patients must dedicate several hours a day to bandages, dressings and care to prevent infections.
The new treatments developed in recent years, based on topical gene therapies, have begun to change this scenario. Stheir main effect is to accelerate the healing of chronic wounds that characterize the disease. In clinical trials, a significant portion of the treated lesions has managed to close in a few months, something that was previously exceptional.
This improvement has a direct impact on quality of life. Fewer wounds mean less pain, lower risk of infections and fewer hospitalizations. It also reduces the time that patients and their families must dedicate each day to dressings, which in the most severe cases can last for several hours.
Mobility is another aspect that can improve. Many patients with epidermolysis bullosa have difficulty walking, manipulating objects or performing daily activities due to wounds on their hands and feet. If these lesions heal more quickly, personal autonomy increases and participation in school, work or social activities is facilitated.
Although these treatments do not yet constitute a definitive cure for the disease, specialists agree that they represent one of the most relevant advances of recent decades. For many patients, the difference can be substantial: going from living with permanent wounds to being able to better control the disease and significantly reduce daily pain.
Andalusia gets ahead of the national system
In this context, the Junta de Andalucía has decided to finance access to one of the most advanced therapies developed so far for the disease. It is a topical gene therapy treatment that helps heal wounds and reduce the chronic pain suffered by patients.
Despite the high price of the medication, the total impact on the Andalusian health system is relatively limited due to the small number of affected individuals. In the autonomous community, it is estimated that there are around 40 or 45 diagnosed patients, which represents a global annual cost of a few million euros within a health budget that exceeds 14,000 million.
A treatment with an unprecedented cost
The estimated cost of the treatment can reach extraordinary figures. Some calculations place the accumulated expenditure per patient throughout their life between nine and twenty million euros.
This price is explained by several factors: the scientific complexity of gene therapies, the reduced number of affected patients, and the enormous investment necessary to develop medicines intended for rare diseases. These circumstances turn this type of therapies into some of the most expensive treatments in modern medicine.
A political decision that comes after the health controversy
The decision of Andalusia also has a political reading. The president of the Junta, Juanma Moreno, has known how to quickly interpret a health problem that was beginning to generate a growing social controversy.
The pressure from families and patient associations, along with the media impact of specific cases, highlighted the lack of access to this treatment in Spain. In that context, the Andalusian Government chose to anticipate the state decision and assume the cost of the medication for the community's patients.
The measure also comes after a complex period for the regional Executive in healthcare matters. The crisis generated by the controversies surrounding the medical screening system and criticisms of healthcare management placed healthcare at the center of the political debate in Andalusia. Since then, Moreno's Executive has intensified initiatives aimed at reinforcing its commitment to the public health system.
Spain versus other countries
The Andalusian decision arrives while the central Government continues evaluating the financing of the medicine for the entire National Health System. In Spain, the incorporation of new drugs requires the negotiation of the price with the pharmaceutical industry and the approval of the Interministerial Commission for Drug Prices, a process that sometimes extends for months or even years.
In other countries, however, access to innovative therapies for epidermolysis bullosa has advanced more rapidly. The United States leads global research in this field thanks to university centers and specialized hospitals that have driven clinical trials of gene therapy. In Europe, countries like France and Italy also have highly specialized hospital networks for rare diseases and have actively participated in the development of experimental treatments.
In data
The Autonomous Communities await the State while Andalusia moves ahead
In most Spanish autonomous communities, the most innovative treatment for epidermolysis bullosa is not yet generally funded.
Although the medication already has European approval, its incorporation into the public system depends on a state decision on price and funding within the National Health System. Meanwhile, regions such as Madrid, Catalonia, Valencian Community, Galicia, or Basque Country continue to primarily offer supportive care, which includes daily wound care, special bandages, pain control, and follow-up by specialized medical teams.
Some hospitals function as reference centers for this disease and concentrate patient care with multidisciplinary teams. The main ones are the La Paz University Hospital (Madrid) and Sant Joan de Déu Barcelona Hospital (Barcelona).
However, access to innovative therapies in Spain has only been possible until now through exceptional case-by-case authorizations.
In this context, Andalusia's decision sets a precedent by becoming the first community to directly assume the cost of treatment for its patients, while the rest of the autonomous communities await a definitive decision from the central Government.
The key role of patient associations
Along with medical research, patient associations have played a key role in making the disease visible and supporting families.
In Spain, the work of DEBRA España stands out, an organization specialized in epidermolysis bullosa that provides medical advice, psychological support, and social assistance to those affected. Internationally, entities such as DEBRA International or Epidermolysis Bullosa Research Partnership promote scientific research and collaborate in the development of new treatments.
For many families, these associations represent a fundamental support in the face of an illness that demands constant care and a high emotional and economic burden.
A precedent for the treatment of rare diseases
The decision of Andalusia -points out the scientific community- does not by itself resolve access to treatment throughout Spain, but it does open a relevant precedent. In the field of rare diseases, where each scientific advance can take years to reach patients, the step taken by the Andalusian community reflects the growing weight of biomedical research and social pressure to accelerate the incorporation of innovative therapies into public health systems.
The map of rare diseases
In Spain, it is estimated that there are between 6,000 and 7,000 rare diseases, pathologies that affect fewer than five people per 10,000 inhabitants. Although each of them has a very low incidence, together they affect around three million people in the country, according to data from patient organizations and health authorities.
Public healthcare addresses these diseases through reference centers, services, and units (CSUR) distributed across different autonomous communities, which concentrate medical expertise in rare pathologies. Treatment varies depending on the disease: in many cases, it is based on symptomatic therapies and supportive care, while in others orphan drugs are used, specific drugs developed for rare diseases that must be evaluated and funded by the National Health System before reaching patients.